These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19131045)

  • 1. Neuroimaging of L-dopamine and dopamine agonist therapy - revisited.
    Fukuyama H
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S53-7. PubMed ID: 19131045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonist-based strategies in the treatment of Parkinson's disease.
    Antonini A; Barone P
    Neurol Sci; 2008 Dec; 29 Suppl 5():S371-4. PubMed ID: 19381765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments of brain imaging for Parkinson's disease and related disorders.
    Piccini P; Brooks DJ
    Mov Disord; 2006 Dec; 21(12):2035-41. PubMed ID: 16874751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.
    Nyholm D
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S13-7. PubMed ID: 17707679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease.
    Fenu S; Wardas J; Morelli M
    Behav Pharmacol; 2009 Sep; 20(5-6):363-79. PubMed ID: 19724195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease.
    Drapier D; Drapier S; Sauleau P; Derkinderen P; Damier P; Allain H; Vérin M; Millet B
    Psychiatry Res; 2006 Nov; 144(2-3):241-4. PubMed ID: 17011634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of early Parkinson's disease. Part 1.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):193-205. PubMed ID: 19176960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimaging of nonmotor features of Parkinson's disease.
    Deblieck C; Wu AD
    Rev Neurol Dis; 2008; 5(3):125-33. PubMed ID: 18838952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
    Baker WL; Silver D; White CM; Kluger J; Aberle J; Patel AA; Coleman CI
    Parkinsonism Relat Disord; 2009 May; 15(4):287-94. PubMed ID: 18774743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective therapy in Parkinson disease.
    Chen S; Le W
    Am J Ther; 2006; 13(5):445-57. PubMed ID: 16988541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is dopamine agonist therapy associated with developing pathological gambling in Parkinson's disease patients?
    Zand R
    Eur Neurol; 2008; 59(3-4):183-6. PubMed ID: 18230877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we image premotor Parkinson disease?
    Marek K; Jennings D
    Neurology; 2009 Feb; 72(7 Suppl):S21-6. PubMed ID: 19221310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonists and therapy compliance.
    Grosset D
    Neurol Sci; 2008 Dec; 29 Suppl 5():S375-6. PubMed ID: 19381766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopamine agonist therapy in early Parkinson's disease. A survey of a Cochrane review].
    Bode M
    Ugeskr Laeger; 2009 Oct; 171(41):2996-9. PubMed ID: 19814927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.